Skip to content
FDAMedicines

Baxter Issues Voluntary Nationwide Recall for Two Lots of 0.9% Sodium Chloride Injection Due to Potential Presence of Particulate Matter

FDA recall n-baxter-issues-voluntary-nationwide-recall-two-lots-09-sodium-chloride-injection- ·

Build snapshot. Collected , once, when this site was built. It is not a live feed.

Check my lot or code

Is yours in this recall?

Type the lot, batch, date code, model number or UPC printed on the product. It is compared here, in your browser, with the codes this notice lists. It stays in this page: it is not added to the address.

General information on recalls from the agency: U.S. Food and Drug Administration (opens in a new tab).

What the agency says to do

FDA’s record gives no instruction for consumers.

Note from Recalls Watch, not agency text

Why it was recalled

Potential presence of particulate matter identified as fiberglass in the solution.
Text from FDA, unedited.

The recalled product

FOR IMMEDIATE RELEASE – AUG. 25, 2026 – DEERFIELD, Ill., Baxter International Inc. (NYSE:BAX) is voluntarily recalling two lots of 0.9% Sodium Chloride Injection due to the potential presence of particulate matter identified as fiberglass in the solution.
Text from FDA, unedited.

Company announcement, as FDA publishes it

FOR IMMEDIATE RELEASE – AUG. 25, 2026 – DEERFIELD, Ill. , Baxter International Inc. (NYSE:BAX) is voluntarily recalling two lots of 0.9% Sodium Chloride Injection due to the potential presence of particulate matter identified as fiberglass in the solution.

Risk Statement: Intravenous administration of 0.9% Sodium Chloride Injection containing fiberglass particulate matter may lead to serious adverse health consequences. Particulate matter can cause blockage and clotting in blood vessels, which can cut off blood flow to vital organs, lead to a life-threatening blood clot in the lungs (pulmonary embolism) and cause permanent organ damage or death. Additionally, these particles may cause local vein irritation, inflammatory reaction, aggravation of preexisting infections, and allergic reactions. As of 8/25/2026, Baxter has not received any reports of adverse events related to this issue.

The product is indicated as a source of water and electrolytes and is also indicated for use as a priming solution in hemodialysis procedures. The product is packaged in 500 mL VIAFLEX Plastic Containers, with 24 units per case. Additional information can be found in the table below.

Affected Product:

The affected lots can be identified by locating the lot number and expiration date on the individual product and shipping carton, as shown in the images below.

The impacted product was distributed from 7/31/2026 to 8/3/2026 to healthcare providers and distributors to select states in the United States, including Florida, Illinois, Indiana, Louisiana, Maryland, Missouri, North Carolina, New Jersey, Nevada, New York, Ohio, South Carolina, Texas, and Virginia.

Customers should immediately discontinue use of and return all affected units in accordance with their facility’s process. Baxter is contacting customers by email with instructions on how to identify and return the impacted product.

Consumers with questions regarding this recall can contact Baxter Healthcare Center for Service at 888-229-0001 between the hours of 7:00 am and 6:00 pm Central Time, Monday through Friday. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Complete and submit the report Online: www.fda.gov/medwatch/report.htm

Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm 2 or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

The United States Food and Drug Administration (FDA) has been notified of this action.

Text from FDA (the company’s words), unedited.
  • 2B1323Q 0.9% Sodium Chloride Injection, USP, 500 mL VIAFLEX Plastic Container

    Lot or code
    Lot Number: Y495523; Expiration ; Date: 31-Oct-2027; NDC Number: 0338-0049-03
  • Y495523A

Source

Issued by
U.S. Food and Drug Administration
Firm
Baxter International Inc.

Check all notices that name this firm in the directory of recalls by brand and manufacturer. This notice is in these lists: Firm: Baxter International Inc., Medicine: Sodium Chloride, Month: August 2026, Week 2026-W35. Browse more medicines recalls, or check another notice by its number in the recall number lookup.

About this recall

What is the hazard?

FDA states: “Potential presence of particulate matter identified as fiberglass in the solution.”

What should I do if I have this product?

FDA’s record gives no instruction for consumers. The official report is linked on this page.

How do I know if my product is included?

Compare the lot or code printed on your product with the codes FDA lists on this notice, product by product.

How does the code check on this page work?

You type the lot, batch, date code, model number or UPC from your package and the page compares it, in your browser, with the codes FDA lists on this notice. It reports a match, a possible match (your code is part of a longer listed code) or no match. It only compares text: a notice that describes products by dates, sizes or “all lots” cannot be compared, so “no match” does not clear a product. The comparison runs in your browser and the page does not send the code anywhere, and the code stays out of the page address. Only if you press “Copy link to this result” is a link made that carries it, and whoever opens that link requests that address from this site.

When was this recall published?

FDA published this company announcement on August 25, 2026.

Other notices of Baxter International Inc.